TY - JOUR T1 - Consensus Statement on the Management of Comorbidity in Patients with Rheumatoid Arthritis and Psoriasis JF - The Journal of Rheumatology JO - J Rheumatol SP - 990 LP - 991 DO - 10.3899/jrheum.151028 VL - 43 IS - 5 AU - SANTOS CASTAÑEDA AU - ESTÍBALIZ LOZA AU - ESTEBAN DAUDÉN AU - LORETO CARMONA Y1 - 2016/05/01 UR - http://www.jrheum.org/content/43/5/990.abstract N2 - To the Editor:We have read with great interest the recommendations for the management of comorbidities in rheumatoid arthritis (RA), psoriasis (PsO), and psoriatic arthritis (PsA) made by the Canadian Dermatology-Rheumatology Comorbidity Initiative1. The work is very interesting and comprehensive, and we congratulate the authors for combining more general recommendations for the management of the comorbidity of these 3 diseases. Indeed, it is sometimes difficult to distinguish between comorbidities, risk factors, medication adverse events, and extraarticular manifestations. But it holds clear that the presence of several different diseases aggravates the monitoring of these patients.We have recently published a consensus statement for the management of comorbidity and extraarticular manifestations in RA2 and a practical derivation algorithm of patients with comorbidity associated with PsO in Spain3. In the mentioned manuscript, the Canadian experts selected 8 main topics regarding comorbidities in RA, PsA, and PsO1. The Spanish panel selected the 10 most relevant comorbidities and risk factors based on a ranking depending on incidence, mortality, and preventability. Interestingly, 8 … Address correspondence to Dr. S. Castañeda, Rheumatology Department, Hospital de La Princesa, IIS-IPrincesa, Universidad Autónoma de Madrid, C/ Diego de Leon 62, 28006-Madrid, Spain. E-mail: scastas{at}gmail.com, santos.castaneda{at}salud.madrid.org ER -